The gist
FutureHouse proposed on May 19, 2025 (arXiv preprint) that ripasudil be studied for dry age-related macular degeneration, an eye disease, using the Robin system. Status: not yet assessed.
DiscoverIA status on October 11, 2026: not evaluated, meaning no third-party evaluation found.
AI draft, not reviewedWhat has not been reviewed?
Text written by an AI (DiscoverIA pipeline), on . The status and its sources come from the registry; only the explanatory text has not been reviewed. A reported error is corrected, then the text is reviewed.
Cite this entry
A single status snapshot since Oct 11, 2026: a citation always points to a dated snapshot.
Cite snapshot 1, Oct 11, 2026
APA citation with the dated link
BibTeX @misc, key discoveria-futurehouse-robin-2025-05-19-r1
@misc{discoveria-futurehouse-robin-2025-05-19-r1,
author = {{DiscoverIA}},
title = {Robin: ripasudil proposed for dry age-related macular degeneration},
howpublished = {DiscoverIA registry, entry futurehouse-robin-2025-05-19},
note = {Status “Not evaluated”, snapshot 1, recorded on October 11, 2026. New result},
year = {2026},
url = {https://discoveria.ai/entry/futurehouse-robin-2025-05-19#releve-1},
urldate = {2026-10-11}
}Dated link opens this snapshot in the history
To understand ≈ 20 s reading time, estimated
What it changes
If the result holds, an AI system would have helped spot a lead for an eye disease. This is a proposal based on laboratory experiments, not an available treatment and not shown in patients.
What remains unclear
No third-party verifier is identified. Some sources other than the preprint give different effect figures that have not been reconciled, and a blog mentions a Nature publication in 2026, which is not confirmed.
Read the paper
Robin: A multi-agent system for automating scientific discovery
What it establishes : The authors describe Robin, a multi-agent system that proposed boosting phagocytosis in the retinal pigment epithelium against dry AMD, then singled out ripasudil, which was then tested on cultured cells.
Where to start : The abstract, then Figure 4 (Section 2.2.3): according to the Finch agent's analysis, ripasudil increases phagocytosis 7.5-fold over the control; the human analysis of the same data gives 1.75-fold.
Written by an AI · reviewed by a human
For experts
Sources, method, key facts, status history, report an error
Status
Not evaluated
Recorded on · arxiv.org
Step 1 of 4 on the scale: not evaluated. Next step: under review.
- Announced
- Recordednot evaluated
- nextTo follow
What this status means
Source reading : Source read through an AI summary (level 2 of 3)
The result is declared neither right nor wrong.
To move to “Under review”: a public review under way. To “Peer reviewed”: a journal publication or a review by named experts.
Sources
- Main sourcearxiv.orgpage read through an AI summary
Method
DiscoverIA status: not evaluated, meaning that no third-party evaluation has been found in the sources read. Set on October 11, 2026 from arxiv.org (page read through a model summary, quotation not rechecked).
Limits
The status source was read through a model summary; its quotation was not rechecked. DiscoverIA has not checked this result itself.
Key facts
- Claimed by
- FutureHouse (Ghareeb et al.)
announced on May 19, 2025 - Nature
- new result
- Field
- Biology and medicine (biology / ophthalmology)
- Checked by
- no verifier identified
- Sources
- 1 : 1 through an AI summary
- This entry
- AI draft, not reviewed
Status history
Only one observation so far.
- 01
First observation:Not evaluatedCurrent status
a blog, seen only in a search-engine snippet, mentions a Nature publication in 2026; not confirmed
Source: arxiv.orgread through an AI summary
An observation is added; none is ever erased.
Report an error or suggest a source
Thank you, your message was sent.
Sending failed. Try again, or write to contact@discoveria.ai.
Is your result listed?What each status requires, correcting this entry, replying to it.